Overview

Detailed Summary

CORONA Remedies Limited is an India‑focused, branded pharmaceutical company that develops, manufactures and markets formulations across women’s healthcare, cardio‑diabeto, pain management, urology and other therapies, operating manufacturing plants in Solan (Himachal Pradesh) and Bhayla/Ahmedabad (Gujarat) with DSIR R&D and multiple GMP certifications supporting domestic and export ambitions.
Financial momentum is healthy: Q3 FY26 revenue of INR 342 crore (+15% YoY) and 9M FY26 revenue of INR 1,050 crore (+16.3%), with EBITDA margins improving to 24.3% in Q3 and 22.0% for 9M, and adjusted PAT up 23.7% in Q3 and 30.7% for 9M, reflecting operating leverage and strong brand economics.
Export runway expanded materially after EAEU‑GMP accreditation for the Gujarat plant, enabling access to five Eurasian markets (Russia, Kyrgyzstan, Armenia, Belarus, Kazakhstan) and a stated addressable pharmaceutical market opportunity of up to approximately USD 25 billion, positioning CORONA Remedies for measured B2B export growth over the next few years.
Brand and go‑to‑market strategy is a core strength: 27 ‘engine’ brands contributed ~72% of domestic sales historically, the company has scaled acquired brands from major multinationals and plans to commercialize the Bayer portfolio including IVF and antiplatelet franchises, supported by ~600 new medical representatives added over recent years.
Strong cash generation underpins growth and returns: OCF/EBITDA of 86.3% and annualised ROCE of 48.0% (9M FY26) demonstrate disciplined working‑capital and capital allocation, enabling reinvestment into product launches, modest capacity additions and selective inorganic opportunities without immediate dependence on external funding.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 10,482 Cr
Volatility: Low Risk
P/E Ratio: 56.6
Industry P/E: 34.1
PEG Ratio: 1.3
P/B Ratio: 13.8
52W High: 1,951.30
52W Low: 1,336.95

Sales CAGR

1Y: 17.94%
3Y: 24.68%
5Y: 14.75%
10Y: —

Profit CAGR

1Y: 65.12%
3Y: —
5Y: 20.20%
10Y: —

ROE

TTM: 24.79%
3Y: 21.70%
5Y: 17.84%
10Y: —

ROCE

TTM: 27.13%
3Y: 26.04%
5Y: 21.76%
10Y: —

Technicals

‌

Forecasts

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
MARKSANS		250.50	11,313 Cr	27.07	3.74	0.36	13.82	17.37	10.88
VIYASH		249.35	10,893 Cr	68.18	3.74	0.00	7.07	13.01	4.44
SANOFICONR		4578.00	10,564 Cr	40.96	27.51	1.63	62.53	75.60	47.15
SHILPAMED		542.30	10,540 Cr	43.32	4.07	0.11	9.39	10.73	6.57
CORONA		1680.00	10,279 Cr	55.53	13.76	0.59	24.79	27.13	15.36
PGHL		6190.00	10,271 Cr	31.42	19.58	6.71	62.32	84.14	38.86
AKUMS		608.65	9,580 Cr	37.54	2.89	0.48	7.70	10.95	4.71
Median: 7 Co.	—	608.65	10,540 Cr	40.96	4.07	0.48	13.82	17.37	10.88

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	314	298	294	347	361	342	353
Expenses	247	228	239	277	283	259	291
Operating Profit	67	69	54	70	78	83	62
OPM %	21.29	23.32	18.46	20.14	21.73	24.29	17.56
Other Income	2.45	0.94	1.63	1.82	2.44	-17	4.39
Interest	2.87	2.39	2.20	1.99	1.93	1.66	1.38
Depreciation	9.05	9.69	10	8.92	9.20	9.45	10
Profit Before Tax	57	58	44	61	70	55	55
Tax %	25.07	22.87	27.65	23.89	25.02	25.25	17.19
Net Profit	43	45	32	46	52	41	45
EPS in Rs	—	—	—	—	—	6.75	7.41

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Sales	884	1,014	1,196
Expenses	756	860	956
Operating Profit	128	155	240
OPM %	14.48	15.25	20.06
Other Income	7.28	6.46	6.32
Interest	4.27	14	11
Depreciation	20	28	37
Profit Before Tax	111	118	199
Tax %	23.41	23.61	24.73
Net Profit	85	91	149
EPS in Rs	—	—	—
Dividend Payout %	19.01	25.00	29.92

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Equity Capital	61	61	61
Reserves	347	419	545
Borrowings	28	159	86
Other Liabilities	159	191	237
Total Liabilities	595	831	930
Fixed Assets	185	384	370
CWIP	65	121	186
Investments	31	26	26
Other Assets	314	301	348
Total Assets	595	831	930

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	103	157	190
Cash from Investing Activity	-50	-267	-84
Cash from Financing Activity	-45	99	-107
Net Cash Flow	7.71	-11	0.07

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Apr 2025	Dec 2025	Mar 2026
Promoters	72.50%	69.00%	69.00%
FIIs	0.00%	1.04%	2.25%
DIIs	27.50%	3.65%	7.02%
Public	0.00%	26.32%	21.74%
Total Shareholders	9	1,59,545	19,609

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Unlock more with professional

Analyst Target, Price, EPS and Revenue Projections
Get In-depth insights on EPS and Revenue forecasts

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY26

Investor Presentation

Q3 FY26

Investor Presentation

Q3 FY26

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Corona Remedies Ltd

Corona Remedies Ltd (CORONA) is currently trading at 1,713.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

CORONA Remedies Limited is an India‑focused, branded pharmaceutical company that develops, manufactures and markets formulations across women’s healthcare, cardio‑diabeto, pain management, urology and other therapies, operating manufacturing plants in Solan (Himachal Pradesh) and Bhayla/Ahmedabad (Gujarat) with DSIR R&D and multiple GMP certifications supporting domestic and export ambitions. Financial momentum is healthy: Q3 FY26 revenue of INR 342 crore (+15% YoY) and 9M FY26 revenue of INR 1,050 crore (+16.3%), with EBITDA margins improving to 24.3% in Q3 and 22.0% for 9M, and adjusted PAT up 23.7% in Q3 and 30.7% for 9M, reflecting operating leverage and strong brand economics. Export runway expanded materially after EAEU‑GMP accreditation for the Gujarat plant, enabling access to five Eurasian markets (Russia, Kyrgyzstan, Armenia, Belarus, Kazakhstan) and a stated addressable pharmaceutical market opportunity of up to approximately USD 25 billion, positioning CORONA Remedies for measured B2B export growth over the next few years. Brand and go‑to‑market strategy is a core strength: 27 ‘engine’ brands contributed ~72% of domestic sales historically, the company has scaled acquired brands from major multinationals and plans to commercialize the Bayer portfolio including IVF and antiplatelet franchises, supported by ~600 new medical representatives added over recent years. Strong cash generation underpins growth and returns: OCF/EBITDA of 86.3% and annualised ROCE of 48.0% (9M FY26) demonstrate disciplined working‑capital and capital allocation, enabling reinvestment into product launches, modest capacity additions and selective inorganic opportunities without immediate dependence on external funding.

Over the past 52 weeks, Corona Remedies Ltd has traded between a low of ₹1,336.95 and a high of ₹1,951.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Corona Remedies Ltd has a market capitalization of approximately 10,279.48. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Corona Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 55.53 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 10,279.48 Cr, Corona Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Corona Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Corona Remedies Ltd is 55.53. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Q3 FY26 revenue from operations was INR 342.42 crore (+15% YoY) and adjusted PAT was INR 55.56 crore (+23.7% YoY), excluding a one-time statutory impact.

Corona Remedies Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Unlock more with professional

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Unlock more with professional

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Corona Remedies Ltd

What is Corona Remedies Ltd share price today?

What does Corona Remedies Ltd do?

What is the 52-week high and low of Corona Remedies Ltd?

What is the market capitalization of Corona Remedies Ltd?

Should I consider investing in Corona Remedies Ltd stock?

Is Corona Remedies Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Corona Remedies Ltd belong to and why does it matter?

What is the PE ratio of Corona Remedies Ltd?

What were Corona Remedies’ Q3 FY26 revenue and PAT numbers?

Investor’s Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Technicals

Forecasts

Unlock more with professional

Projection

Unlock more with professional

Frequently Asked Questions about Corona Remedies Ltd

What is Corona Remedies Ltd share price today?

What does Corona Remedies Ltd do?

What is the 52-week high and low of Corona Remedies Ltd?

What is the market capitalization of Corona Remedies Ltd?

Should I consider investing in Corona Remedies Ltd stock?

Is Corona Remedies Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Corona Remedies Ltd belong to and why does it matter?

What is the PE ratio of Corona Remedies Ltd?

What were Corona Remedies’ Q3 FY26 revenue and PAT numbers?

Announcements

Oscillators

Neutral

Overall

Neutral

Moving Averages

Bullish

Overall

Neutral

Peers

Price Chart Comparison

Overview

Financial Ratios

Investment Checklist